Preemptive use of plerixafor in difficult‐to‐mobilize patients: an emerging concept
- 7 October 2011
- journal article
- review article
- Published by Wiley in Transfusion
- Vol. 52 (4), 906-914
- https://doi.org/10.1111/j.1537-2995.2011.03349.x
Abstract
Mobilized peripheral blood (PB) is the preferred source of stem cells (PBSCs) for autologous stem cell transplantation (ASCT). The use of cytokines, alone or in combination with chemotherapy (chemomobilization), is currently the most common strategy applied to collect PBSCs. However, a significant proportion of patients with lymphoid malignancies fail to mobilize enough PBSCs to proceed to ASCT. Plerixafor has been recently introduced for clinical use to enhance PBSC mobilization and has been shown to be more effective than granulocyte-colony-stimulating factor (G-CSF) alone in patients with multiple myeloma or non-Hodgkin's lymphoma. There is limited experience on combining plerixafor with chemotherapy plus G-CSF in patients who mobilize poorly. This review attempts to summarize the published experience on the preemptive use of plerixafor after chemomobilization or G-CSF mobilization to enhance stem cell collection and to prevent mobilization failure. Current evidence suggests that addition of plerixafor is safe and effective in the large majority of the patients with low blood CD34+ cell counts after mobilization and/or poor yield after the first collection(s). Circulating CD34+ cell counts can be increased by severalfold with plerixafor and the majority of the patients considered difficult to mobilize can be successfully collected. Although more studies are needed to evaluate proper patient selection and optimal timing for the addition of plerixafor after chemotherapy, its mechanism of action inducing the rapid release of CD34+ cells from the marrow to the PB makes this molecule suitable for its "preemptive" use in patients who are difficult to mobilize.Keywords
This publication has 45 references indexed in Scilit:
- Mobilization strategies in hard‐to‐mobilize patients with lymphoid malignanciesEuropean Journal of Haematology, 2010
- review: Current status of stem cell mobilizationBritish Journal of Haematology, 2010
- Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous TransplantationTransplantation and Cellular Therapy, 2010
- The EBMT activity survey 2008: impact of team size, team density and new trendsBone Marrow Transplantation, 2010
- Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaAmerican Journal of Hematology, 2009
- Improving stem cell mobilization strategies: future directionsBone Marrow Transplantation, 2009
- Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous TransplantationTransplantation and Cellular Therapy, 2008
- Infused CD34+ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B‐cell lymphoma and follicular lymphoma grade 3 treated with high‐dose therapyBritish Journal of Haematology, 2004
- Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantationBone Marrow Transplantation, 2002
- Defining a Therapeutic Dose of Peripheral Blood Stem CellsJournal of Hematotherapy, 1992